Study #2015-0921
Phase II Study of Inotuzumab Ozogamicin in Patients with B-cell Lineage Acute Lymphocytic Leukemia with Positive Minimal Residual Disease
MD Anderson Study Status
Enrolling
Treatment Agent
Inotuzumab Ozogamicin
Description
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic agent called ozogamicin. Inotuzumab ozogamicin attaches to B cell-specific CD22 cancer cells in a targeted way and kills them.
Information and next steps
Disease:
Acute Lymphoblastic Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent B Acute Lymphoblastic Leukemia
Study phase:
II
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.